Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma

Approximately 80% of low-grade glioma (LGGs) harbor mutant isocitrate dehydrogenase 1/2 (IDH1/2) driver mutations leading to accumulation of the oncometabolite 2-hydroxyglutarate (2-HG). Thus, inhibition of mutant IDH is considered a potential therapeutic target. Several mutant IDH inhibitors are cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Radoul, Marina, Hong, Donghyun, Gillespie, Anne Marie, Najac, Chloé, Viswanath, Pavithra, Pieper, Russell O., Costello, Joseph F., Luchman, Hema Artee, Ronen, Sabrina M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917625/
https://www.ncbi.nlm.nih.gov/pubmed/33668509
http://dx.doi.org/10.3390/metabo11020109

Ejemplares similares

Ejemplares similares